Evaluation of the Efficacy and Safety of Different Doses of SY-004 in Patients With Type 2 Diabetes Mellitus
Latest Information Update: 21 May 2022
At a glance
- Drugs Globalagliatin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Yabao Pharmaceutical Group
Most Recent Events
- 17 May 2022 Status changed from recruiting to completed.
- 15 May 2021 Planned primary completion date changed from 30 Jun 2020 to 30 Jun 2021.
- 06 Jan 2020 New trial record